# Pacific Biosciences of California, Inc.: financial statements, quarterly

PACB · Nasdaq · CIK 1299130 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pacb.md) · [Financials](/companies/pacb/financials.md) · [Filings](/companies/pacb/filings.md) · [Insiders](/companies/pacb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pacb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [55.7](/filings/0001299130-24-000183.md) | [58.4 d](/filings/0001299130-26-000034.md) | [38.8](/filings/0001299130-25-000102.md) | [36.0](/filings/0001299130-25-000156.md) | [40.0](/filings/0001299130-25-000168.md) | [39.2 d](/filings/0001299130-26-000034.md) | [37.2](/filings/0001299130-26-000081.md) | [39.8](/filings/0001299130-26-000122.md) | [38.4](/filings/0001299130-25-000168.md) | [44.6 d](/filings/0001299130-26-000034.md) | [37.2](/filings/0001299130-26-000081.md) | [39.0](/filings/0001299130-26-000122.md) |
| Cost of revenue | $m | [37.8](/filings/0001299130-24-000183.md) | [48.8 d](/filings/0001299130-26-000034.md) | [27.5](/filings/0001299130-25-000102.md) | [30.1](/filings/0001299130-25-000156.md) | [30.0](/filings/0001299130-25-000168.md) | [29.2 d](/filings/0001299130-26-000034.md) | [38.5](/filings/0001299130-26-000081.md) | [25.1](/filings/0001299130-26-000122.md) | [22.5](/filings/0001299130-25-000168.md) | [28.1 d](/filings/0001299130-26-000034.md) | [24.3](/filings/0001299130-26-000081.md) | [26.4](/filings/0001299130-26-000122.md) |
| Gross profit | $m | [17.9](/filings/0001299130-24-000183.md) | [9.6 d](/filings/0001299130-26-000034.md) | [11.3](/filings/0001299130-25-000102.md) | [5.9](/filings/0001299130-25-000156.md) | [10.0](/filings/0001299130-25-000168.md) | [10.1 d](/filings/0001299130-26-000034.md) | [(1.4)](/filings/0001299130-26-000081.md) | [14.7](/filings/0001299130-26-000122.md) | [15.9](/filings/0001299130-25-000168.md) | [16.6 d](/filings/0001299130-26-000034.md) | [12.8](/filings/0001299130-26-000081.md) | [12.6](/filings/0001299130-26-000122.md) |
| Research and development | $m | [47.5](/filings/0001299130-24-000183.md) | [44.5 d](/filings/0001299130-26-000034.md) | [43.5](/filings/0001299130-25-000102.md) | [38.5](/filings/0001299130-25-000156.md) | [25.5](/filings/0001299130-25-000168.md) | [27.5 d](/filings/0001299130-26-000034.md) | [29.1](/filings/0001299130-26-000081.md) | [22.5](/filings/0001299130-26-000122.md) | [22.8](/filings/0001299130-25-000168.md) | [22.9 d](/filings/0001299130-26-000034.md) | [19.6](/filings/0001299130-26-000081.md) | [23.0](/filings/0001299130-26-000122.md) |
| Selling, general and administrative | $m | [43.4](/filings/0001299130-24-000183.md) | [46.0 d](/filings/0001299130-26-000034.md) | [43.8](/filings/0001299130-25-000102.md) | [45.9](/filings/0001299130-25-000156.md) | [43.7](/filings/0001299130-25-000168.md) | [41.6 d](/filings/0001299130-26-000034.md) | [40.2](/filings/0001299130-26-000081.md) | [36.2](/filings/0001299130-26-000122.md) | [31.1](/filings/0001299130-25-000168.md) | [34.1 d](/filings/0001299130-26-000034.md) | [31.2](/filings/0001299130-26-000081.md) | [33.4](/filings/0001299130-26-000122.md) |
| Operating income | $m | [(82.5)](/filings/0001299130-24-000183.md) | [(87.5) d](/filings/0001299130-26-000034.md) | [(81.4)](/filings/0001299130-25-000102.md) | [(176)](/filings/0001299130-25-000156.md) | [(64.1)](/filings/0001299130-25-000168.md) | [(153) d](/filings/0001299130-26-000034.md) | [(429)](/filings/0001299130-26-000081.md) | [(44.9)](/filings/0001299130-26-000122.md) | [(38.9)](/filings/0001299130-25-000168.md) | [(41.2) d](/filings/0001299130-26-000034.md) | [(8.4)](/filings/0001299130-26-000081.md) | [(44.6)](/filings/0001299130-26-000122.md) |
| Interest expense | $m | [3.6](/filings/0001299130-23-000139.md) | [3.6 d](/filings/0001299130-24-000054.md) | [3.6](/filings/0001299130-24-000111.md) | [3.5](/filings/0001299130-25-000156.md) | [3.5](/filings/0001299130-25-000168.md) | [2.8 d](/filings/0001299130-26-000034.md) | [1.7](/filings/0001299130-26-000081.md) | [1.7](/filings/0001299130-26-000122.md) | [1.7](/filings/0001299130-25-000168.md) | [1.7 d](/filings/0001299130-26-000034.md) | [1.7](/filings/0001299130-26-000081.md) | [2.1](/filings/0001299130-26-000122.md) |
| Income tax | $m | [(10.7)](/filings/0001299130-24-000183.md) | [(0.7) d](/filings/0001299130-26-000034.md) | [0.0](/filings/0001299130-25-000102.md) | [0.0](/filings/0001299130-25-000156.md) | [0.0](/filings/0001299130-25-000168.md) | [0.3 d](/filings/0001299130-26-000034.md) | [(0.3)](/filings/0001299130-26-000081.md) | [0.0](/filings/0001299130-26-000122.md) | [0.4](/filings/0001299130-25-000168.md) | [0.2 d](/filings/0001299130-26-000034.md) | [0.2](/filings/0001299130-26-000081.md) | [0.1](/filings/0001299130-26-000122.md) |
| Net income | $m | [(66.9)](/filings/0001299130-24-000183.md) | [(82.0) d](/filings/0001299130-26-000034.md) | [(78.2)](/filings/0001299130-25-000102.md) | [(173)](/filings/0001299130-25-000156.md) | [(60.7)](/filings/0001299130-25-000168.md) | [2.4 d](/filings/0001299130-26-000034.md) | [(426)](/filings/0001299130-26-000081.md) | [(41.9)](/filings/0001299130-26-000122.md) | [(38.0)](/filings/0001299130-25-000168.md) | [(40.4) d](/filings/0001299130-26-000034.md) | [(8.3)](/filings/0001299130-26-000081.md) | [(44.7)](/filings/0001299130-26-000122.md) |
| Diluted EPS | $ per share | [(0.26)](/filings/0001299130-24-000183.md) | not reported | [(0.29)](/filings/0001299130-25-000102.md) | [(0.64)](/filings/0001299130-25-000156.md) | [(0.22)](/filings/0001299130-25-000168.md) | not reported | [(1.44)](/filings/0001299130-26-000081.md) | [(0.14)](/filings/0001299130-26-000122.md) | [(0.13)](/filings/0001299130-25-000168.md) | not reported | [(0.03)](/filings/0001299130-26-000081.md) | [(0.14)](/filings/0001299130-26-000122.md) |
| Basic EPS | $ per share | [(0.26)](/filings/0001299130-24-000183.md) | not reported | [(0.29)](/filings/0001299130-25-000102.md) | [(0.64)](/filings/0001299130-25-000156.md) | [(0.22)](/filings/0001299130-25-000168.md) | not reported | [(1.44)](/filings/0001299130-26-000081.md) | [(0.14)](/filings/0001299130-26-000122.md) | [(0.13)](/filings/0001299130-25-000168.md) | not reported | [(0.03)](/filings/0001299130-26-000081.md) | [(0.14)](/filings/0001299130-26-000122.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [386](/filings/0001299130-24-000183.md) | [180](/filings/0001299130-26-000034.md) | [76.6](/filings/0001299130-25-000102.md) | [99.5](/filings/0001299130-25-000156.md) | [78.0](/filings/0001299130-25-000168.md) | [55.4](/filings/0001299130-26-000034.md) | [58.5](/filings/0001299130-26-000081.md) | [54.8](/filings/0001299130-26-000122.md) | [56.5](/filings/0001299130-25-000168.md) | [63.7](/filings/0001299130-26-000122.md) | [56.3](/filings/0001299130-26-000081.md) | [61.0](/filings/0001299130-26-000122.md) |
| Current assets | $m | [882](/filings/0001299130-23-000139.md) | [742](/filings/0001299130-25-000061.md) | [677](/filings/0001299130-24-000111.md) | [628](/filings/0001299130-24-000169.md) | [584](/filings/0001299130-24-000183.md) | [496](/filings/0001299130-26-000034.md) | [445](/filings/0001299130-25-000102.md) | [413](/filings/0001299130-25-000156.md) | [394](/filings/0001299130-25-000168.md) | [375](/filings/0001299130-26-000122.md) | [370](/filings/0001299130-26-000081.md) | [339](/filings/0001299130-26-000122.md) |
| Total assets | $m | [1,898](/filings/0001299130-23-000139.md) | [1,746](/filings/0001299130-25-000061.md) | [1,670](/filings/0001299130-24-000111.md) | [1,509](/filings/0001299130-24-000169.md) | [1,450](/filings/0001299130-24-000183.md) | [1,260](/filings/0001299130-26-000034.md) | [861](/filings/0001299130-25-000102.md) | [825](/filings/0001299130-25-000156.md) | [803](/filings/0001299130-25-000168.md) | [784](/filings/0001299130-26-000122.md) | [782](/filings/0001299130-26-000081.md) | [752](/filings/0001299130-26-000122.md) |
| Current liabilities | $m | [184](/filings/0001299130-23-000139.md) | [95.0](/filings/0001299130-25-000061.md) | [73.0](/filings/0001299130-24-000111.md) | [78.4](/filings/0001299130-24-000169.md) | [60.0](/filings/0001299130-24-000183.md) | [66.3](/filings/0001299130-26-000034.md) | [66.6](/filings/0001299130-25-000102.md) | [59.8](/filings/0001299130-25-000156.md) | [63.2](/filings/0001299130-25-000168.md) | [72.8](/filings/0001299130-26-000122.md) | [65.4](/filings/0001299130-26-000081.md) | [68.8](/filings/0001299130-26-000122.md) |
| Total liabilities | $m | [1,135](/filings/0001299130-23-000139.md) | [1,045](/filings/0001299130-25-000061.md) | [1,021](/filings/0001299130-24-000111.md) | [1,017](/filings/0001299130-24-000169.md) | [997](/filings/0001299130-24-000183.md) | [754](/filings/0001299130-26-000034.md) | [769](/filings/0001299130-25-000102.md) | [764](/filings/0001299130-25-000156.md) | [767](/filings/0001299130-25-000168.md) | [779](/filings/0001299130-26-000122.md) | [780](/filings/0001299130-26-000081.md) | [785](/filings/0001299130-26-000122.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | [0.5](/filings/0001299130-25-000061.md) | not reported | not reported | not reported | [0.0](/filings/0001299130-25-000061.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [764](/filings/0001299130-24-000183.md) | [701](/filings/0001299130-26-000034.md) | [649](/filings/0001299130-25-000156.md) | [493](/filings/0001299130-25-000168.md) | [453](/filings/0001299130-25-000168.md) | [507](/filings/0001299130-26-000122.md) | [91.6](/filings/0001299130-26-000122.md) | [61.5](/filings/0001299130-26-000122.md) | [36.1](/filings/0001299130-25-000168.md) | [5.3](/filings/0001299130-26-000122.md) | [2.4](/filings/0001299130-26-000122.md) | [(33.2)](/filings/0001299130-26-000122.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(65.2) d](/filings/0001299130-24-000183.md) | [(57.6) d](/filings/0001299130-26-000034.md) | [(75.7)](/filings/0001299130-25-000102.md) | [(54.3) d](/filings/0001299130-25-000156.md) | [(45.5) d](/filings/0001299130-25-000168.md) | [(30.7) d](/filings/0001299130-26-000034.md) | [(44.1)](/filings/0001299130-26-000081.md) | [(29.4) d](/filings/0001299130-26-000122.md) | [(18.7) d](/filings/0001299130-25-000168.md) | [(19.1) d](/filings/0001299130-26-000034.md) | [(44.7)](/filings/0001299130-26-000081.md) | [(35.6) d](/filings/0001299130-26-000122.md) |
| Capital expenditure | $m | [0.8 d](/filings/0001299130-24-000183.md) | [2.0 d](/filings/0001299130-26-000034.md) | [3.9](/filings/0001299130-25-000102.md) | [1.5 d](/filings/0001299130-25-000156.md) | [(0.8) d](/filings/0001299130-25-000168.md) | [1.6 d](/filings/0001299130-26-000034.md) | [1.4](/filings/0001299130-26-000081.md) | [0.6 d](/filings/0001299130-26-000122.md) | [(0.1) d](/filings/0001299130-25-000168.md) | [0.9 d](/filings/0001299130-26-000034.md) | [3.0](/filings/0001299130-26-000081.md) | [1.6 d](/filings/0001299130-26-000122.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [225](/filings/0001299130-23-000139.md) | [242](/filings/0001299130-24-000111.md) | [250](/filings/0001299130-24-000169.md) | [255](/filings/0001299130-24-000183.md) | [270](/filings/0001299130-25-000102.md) | [272](/filings/0001299130-25-000156.md) | [273](/filings/0001299130-25-000168.md) | [297](/filings/0001299130-26-000081.md) | [300](/filings/0001299130-26-000122.md) | [301](/filings/0001299130-25-000168.md) | [306](/filings/0001299130-26-000081.md) | [311](/filings/0001299130-26-000122.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 310,830,759 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001299130-26-000122.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.